SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
BURLINGAME, Calif., March 13, 2017 -- Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced that the company will postpone its R&D Day scheduled for March 14, 2017 due to an anticipated severe winter snowstorm forecasted to hit the New York tri-state area and its impact on the travel schedule and participation of its principal presenters.
The company plans to reschedule the event within the first half of 2017 and will provide details of the rescheduled event as soon as that date is determined.
The company anticipates providing additional updates on its lead CPI-444 program as planned at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® is a registered trademark of Genentech.
Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. +1-650-900-4511 [email protected] Media Contact Julie Normart Pure Communications +1-415-946-1087 [email protected]
